Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (23 Mar 2018), |
Regulation- |


| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| HER2 Positive Colorectal Cancer | Japan | 01 Oct 2023 | |
| HER2 Positive Breast Cancer | Japan | 28 Nov 2018 | |
| HER2-positive gastric cancer | Japan | 23 Mar 2018 |






